The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
 
Raquibul Hannan
No Relationships to Disclose
 
Se Eun Kim
No Relationships to Disclose
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Procept Biorobotics
 
Elizabeth Marie Wulff-Burchfield
Stock and Other Ownership Interests - Immunomedics (I); Nektar (I)
Consulting or Advisory Role - Aptitude Health; Astellas Scientific and Medical Affairs Inc; AVEO; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Targeted Oncology
Research Funding - Acerta Pharma/AstraZeneca (Inst); Pfizer
Patents, Royalties, Other Intellectual Property - Methods of use patent application has been submitted for the pharmaceutical product Osanetant, owned by Acer Therapeutics.
 
Andrew Wentland
No Relationships to Disclose
 
Mu-Han Hannan
No Relationships to Disclose
 
Payal Kapur
No Relationships to Disclose
 
Daniel Shevrin
No Relationships to Disclose
 
Tami Gurley
No Relationships to Disclose
 
John Kent Lin
No Relationships to Disclose
 
James Brugarolas
Consulting or Advisory Role - Exelixis; Johnson & Johnson; Telix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - U.S. Application Number: 17/153,128 “PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha” (Inst); U.S. Application Number: 17/206,895 “BIOMARKERS OF RESPONSE TO HIF-2alpha INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF” (Inst); U.S. Patent: US 11,576,889 B2 "METHODS OF IDENTIFYING AND TREATING PATIENTS WITH HIF-2 INHIBITOR RESISTANCE" (Inst)
 
Robert D. Timmerman
Consulting or Advisory Role - ImmuneSensor Therapeutics; Reflexion Medical
Research Funding - Accuray (Inst); Elekta (Inst); Varian Medical Systems (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Lynne I. Wagner
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Celgene
 
Naomi B. Haas
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Expert Testimony - Lilly (I)
 
Michael Anthony Carducci
Consulting or Advisory Role - Acrivon Therapeutics; AstraZeneca; Pfizer; Sanofi
Speakers' Bureau - Remedica
Research Funding - Arcus Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Merck (Inst); pfizer (Inst)